Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Apr 2;27(1):46.
doi: 10.1007/s11883-025-01283-1.

The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention

Chukwuemezie Kamanu  1 , Dean G Karalis  2
Affiliations
Review

The Role of Non-Statin Lipid Lowering Therapies to Reduce ASCVD Events in Primary Prevention

Chukwuemezie Kamanu et al. Curr Atheroscler Rep. .

Abstract

Purpose of review: Atherosclerotic cardiovascular disease (ASCVD) remains a leading global health challenge, with low-density lipoprotein (LDL) cholesterol a pivotal risk factor. While statins are cornerstone therapy for lowering LDL cholesterol, many high-risk primary prevention patients are unable to tolerate statin therapy and do not achieve their guideline directed LDL cholesterol goal. For these patients, non-statin therapies offer complementary and alternative approaches to LDL cholesterol reduction.

Recent findings: Recent advancements in non-statin therapies have expanded the options available to clinicians to lower LDL cholesterol in high-risk primary prevention patients. Yet these medications are often under-utilized in clinical practice. Observational studies, Mendelian randomization studies, and randomized clinical trials support the role of non-statin LDL cholesterol lowering therapies in the primary prevention of ASCVD. This review summarizes the evidence supporting their use for the primary prevention of ASCVD and offers practical suggestions as to how clinicians can integrate these medications into their clinical practice.

Keywords: LDL cholesterol reduction; Lipid-lowering therapies; Non-statin therapies; Primary prevention.

PubMed Disclaimer

Conflict of interest statement

Declarations. Human and Animal Rights and Informed Consent: All studies included in this review are published and followed ethical standards. Competing Interests: Dr. Karalis has received research grant support from Amgen, Regeneron, and Novartis, is a consultant for Esperion and Novartis, and is on the speaker’s bureau for Novartis, Esperion, and Amgen.

References

    1. Martin SS, Aday AW, Almarzooq ZI, et al. Circulation. 2024;149(8):e347–913. 10.1161/CIR.0000000000001209. 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association. - PubMed
    1. Woodruff RC, Tong X, Khan SS, et al. Trends in cardiovascular disease mortality rates and excess deaths, 2010–2022. Am J Prev Med. 2024;66(4):582–9. 10.1016/j.amepre.2023.11.009. - PMC - PubMed
    1. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of Statin therapy. Lancet. 2016;388(10059):2532–61. 10.1016/s0140-6736(16)31357-5. - PubMed
    1. Grundy SM, Stone NJ, Bailey AL, NLA/PCNA Guideline on the Management of Blood Cholesterol. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2019;139(25). 10.1161/cir.0000000000000625. - PMC - PubMed
    1. Cheeley MK, Saseen JJ, Agarwala A, et al. NLA scientific statement on Statin intolerance: a new definition and key considerations for ASCVD risk reduction in the Statin intolerant patient. J Clin Lipidol. 2022;16(4):361–75. 10.1016/j.jacl.2022.05.068. - PubMed

MeSH terms

Substances